Latham & Watkins Advises Phathom Pharmaceuticals in its Formation, Financing and License Agreement with Takeda

The new company focuses on the development and commercialization of novel treatments for gastrointestinal diseases.

May 17, 2019

Takeda Pharmaceutical Company Limited (“Takeda”) and Frazier Healthcare Partners (“Frazier”) have announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. Takeda has granted a license to Phathom for the development and exclusive commercialization rights to vonoprazan in the United States, Europe and Canada in exchange for upfront cash and equity, as well as future cash milestones and royalties on net sales. In connection with the license, Phathom has completed a US$90 million crossover financing and US$50 million debt facility. 

Latham & Watkins LLP represented Phathom Pharmaceuticals in the transaction. San Diego partner Cheston Larson advised on venture financing matters; San Diego/Silicon Valley partner Chris Hazuka advised on licensing matters; and San Francisco partner Haim Zaltzman advised on the debt financing matters.

 

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.